Enliven Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ELVN and other ETFs, options, and stocks.

About ELVN

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates.

CEO

Samuel S. Kintz

CEOSamuel S. Kintz

Employees

Employees62

Headquarters

Boulder, Colorado

HeadquartersBoulder, Colorado

Founded

2019

Founded2019

Employees

Employees62

ELVN Key Statistics

Market cap

929.61M

Market cap929.61M

Price-Earnings ratio

-9.97

Price-Earnings ratio-9.97

Dividend yield

—

Dividend yield—

Average volume

244.35K

Average volume244.35K

High today

$19.22

High today$19.22

Low today

$17.82

Low today$17.82

Open price

$18.41

Open price$18.41

Volume

153.27K

Volume153.27K

52 Week high

$30.03

52 Week high$30.03

52 Week low

$13.30

52 Week low$13.30

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own ELVN. This list is generated using Robinhood data, and it’s not a recommendation.

Enliven Therapeutics

Why Robinhood?

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. Show more

ELVN Key Statistics

Analyst ratings

100%

People also own

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates.